Filing Flows › Korro Bio (KRRO) › Q1 2025
Korro Bio (KRRO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Korro Bio (KRRO) reported revenue of $2.5M for the first quarter 2025 (Q1 2025) and +12% from the quarter before. Operating margin was -981.2%, net loss $23.4M (917.1% of revenue).
Korro Bio, Q1 2025: revenue $2.5M, operating margin -981.2%, net loss $23.4M, operating cash flow −$24.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5M | +12% | — |
| Operating profit | −$25.0M | — | — |
| Net earnings | −$23.4M | — | — |
| Operating cash flow | −$24.5M | — | — |
What changed
Revenue was $2.5M in Q1 2025, up 12% from the previous quarter.
Operating costs exceeded revenue by $25.0M, an operating margin of -981.2%. The quarter ended with a net loss of $23.4M, wider than the previous quarter's $21.2M loss.
Operating cash flow was −$24.5M. Non-cash charges added back $1.2M of depreciation and $1.8M of share-based compensation. Working capital and other items used $4.1M. Capital expenditures of $119K exceeded it, leaving free cash flow of −$24.6M.
Questions
What was Korro Bio's revenue in the first quarter 2025?
Korro Bio (KRRO) reported revenue of $2.5M for the first quarter 2025 (Q1 2025) and +12% from the quarter before.
Was Korro Bio profitable in the first quarter 2025?
Operating loss was $25.0M (-981.2% of revenue) and net loss $23.4M.
Source: Korro Bio 10-Q on SEC EDGAR.